Article Text

Download PDFPDF
Oral vitamin K did not reduce bleeding in patients with excessive anticoagulation after receiving warfarin

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

STUDY DESIGN

Design:

randomised, placebo-controlled trial. ClinicalTrials.gov NCT00143715.

Allocation:

concealed.*

Blinding:

blinded (patients, clinicians, research coordinators, and outcome adjudicators).*

STUDY QUESTION

Setting:

14 anticoagulant centres in the USA, Canada, and Italy.

Patients:

724 outpatients ⩾18 years of age (mean age 69 y, 53% men) who attended clinic for routine international normalised ratio (INR) assessment, were receiving warfarin with a target INR of 2.0–3.5, were not bleeding, and had an INR between 4.5 and 10.0 in the past 24 hours. Exclusion criteria included life expectancy <10 days, indication for acute normalisation of INR, scheduled discontinuation of warfarin, known bleeding disorder, recent major bleeding, inability to take oral medication or undergo follow-up, contraindication to vitamin K, severe liver disease, thrombolytic therapy within 48 hours, and …

View Full Text

Footnotes

  • Source of funding: Canadian Institutes of Health Research and Italian Ministry of Universities and Research.